Glaukos Corporation Glaukos Corporation

Glaukos Corporation

GKOS

Rang in Aktien #2087
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Aktienkurs
$166.79
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$9.84B
Veränderung (1 Tag)
1.44%
Veränderung (1 Jahr)
109.88%
Land
US
Handel Glaukos Corporation (GKOS)

Kategorie

Healthcare
Aktien-Split-Historie für Glaukos Corporation (GKOS)
Die Aktie Glaukos Corporation (Symbol: GKOS) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Oct 20, 2026 statt.
Eine GKOS-Aktie, die vor dem Oct 20, 2026 gekauft wurde, entspricht heute 0 GKOS-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
9 x285
US
7 x127
IE
9 x162
US
2 x4
US
0 -
DE